Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
November 01, 2018 09:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Present at two Investor Conferences in November 2018
October 29, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
October 24, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA
October 01, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
Remlarsen treatment increased corneal re-epithelialization, decreased corneal scar formation, and repressed the expression of several pro-fibrotic genes when compared to placebo treated eyes in a...
miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 07, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
Cobomarsen expansion indication data released; first observations from the ongoing Phase 1 clinical trial on safety and efficacy of cobomarsen in ATLL patients, additional data expected by year endNew...
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
August 06, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development...
miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
July 31, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., July 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018
July 25, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
July 10, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting
June 04, 2018 07:30 ET
|
Miragen Therapeutics, Inc.
First two patients with aggressive forms of adult T-cell leukemia/lymphoma treated with cobomarsen demonstrated greater than five months of clinical response with improvement in objective disease...